In The News

Apr 30, 2014 | BioAtla Receives Broad Patent Covering Conditionally Active Biologics

Proprietary “Smart Antibodies” Allow for Selective Activation in Cancerous Tissues

 

SAN DIEGO, Calif. – April 30, 2014 – BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,709,755, its first patent directed to methods of generating conditionally active antibodies.  Conditionally active antibodies are discovered using sophisticated protein evolution technologies for generating therapeutics that are activated in selected microenvironments within the body, such as those indicative of cancerous tumors.   BioAtla’s patent covers method-independent approaches of evolving these conditionally active antibodies, thereby providing a novel mechanism for antibody selectivity.

 

“BioAtla’s Conditionally Active Biologics (CABs) antibody platform represents a disruptive technology for the development of a powerful new class of immunotherapeutics,” said Jay M. Short, Ph.D., president, chief executive officer and chairman of the board of BioAtla. “CABs can be designed to target specific tissues in cancerous or distressed conditions associated with unique microenvironments in the body.  Most importantly, our technology increases the number of possible tumor targets, improves the selectivity of existing targets, enhances therapeutic safety and enables increased potency of antibody therapeutics by expanding the opportunity to use antibody drug conjugates.”

 

“BioAtla’s new platform is an important extension of its proprietary protein evolution capabilities that the company has been developing and applying to drug discovery and development for many years. Our first partnered proprietary CAB in development is an anti-tumor compound targeting the KRAS-positive cancers including colorectal, pancreatic and non-small cell lung cancers. The CAB discovery platform promises several novel product candidates and unprecedented “biobetter” antibodies as our strategic direction expands to include developing highly differentiated compounds for our internal pipeline, as well as for our partners. Advancing this class of smart therapeutics offers the hope of new cures for treating devastating, currently untreatable cancers.” Dr. Short continued.

 

About Conditionally Active Biologics (CABs)

Conditionally Active Biologic proteins (CABs) are generated using BioAtla’s proprietary protein evolution technologies that typically employ uniquely selected amino acid substitutions in a protein that work together to confer selective conditional activation. These proteins can be monoclonal antibodies (mAbs) or enzymes designed with functions dependent on changes in microphysiological conditions (e.g., pH level, oxidation, temperature, pressure, presence of certain ions, hydrophobicity and combinations thereof).

 

Studies have shown that cancerous tumors create highly specific conditions at their site that are not present in normal tissue. These cancerous microenvironments are a result of the well understood unique glycolytic metabolism associated with cancer cells, referred to as the Warburg Effect, which was first identified in the 1920’s and is the basis of the widely-used PET scan cancer detection method today. CAB-designed mAbs can be programmed to deliver their therapeutic payload and/or recruit the immune response in specific and selected locations and conditions within the body. CABs increase safety because the drug is activated when it preferentially binds directly to its intended target protein in the area of disease. In this example, the CAB does not effectively bind to the same protein located in healthy tissue or other part of the body that otherwise results in undesirable toxicity.

 

CABs allow for higher dosing, the development of effective, non-immunogenic drugs, and the use of targets that are validated for cancer cells but traditionally considered too prevalent among normal cells to be used safely in current drug therapies. This opens a potentially rich range of targets for CABs that cannot be addressed using existing technologies. CABs may also be employed as diagnostic tools to reveal and pinpoint conditions indicative of cancerous activity.

 

About BioAtla, LLC

BioAtla is a global biotechnology company with operations in San Diego, California, and Beijing, China. BioAtla develops novel monoclonal antibody and other protein therapeutic products with more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing. By utilizing its proprietary technologies of product design and development, from target discovery to manufacturing and preclinical studies, BioAtla develops differentiated, patentable therapeutic proteins for its partners and for its internal programs. BioAtla has over 70 patents issued and pending that cover its platform technologies representing a full complement of therapeutic protein development capabilities. Learn more at www.bioatla.com.

 

# # #

Contacts:
Richard Waldron

Chief Financial Officer

BioAtla

rwaldron@bioatla.com

858.356.8945

Mar 18, 2014 | BioAtla Successfully Completes Engineering of Telephus Medical Antibody TPH 101 for Prevention of Infection in Septic Revision Hip and Knee Arthroplasty

Telephus Advances TPH 101 Program Towards Candidate Selection

SAN DIEGO, Calif. – March 18, 2014 – BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, and Telephus Medical LLC, a leader in the development of vaccine products to prevent periprosthetic joint infections and accompanying osteomyelitis in orthopedic procedures, today announced that BioAtla has successfully completed a key protein engineering phase of Telephus’ compound TPH 101. TPH 101 is Telephus’ lead program focused on the development of neutralizing antibodies targeting a key bacterial enzyme that drives the formation of antibiotic-resistant biofilm infections on implanted medical devices.

 

“We believe Telephus has created a significant franchise in the field for preventing drug-resistant biofilm infections,” said Jay M. Short, Ph.D., president and chief executive officer of BioAtla. “This partnership is an ideal demonstration of the reliability and effectiveness of our proprietary platform to rapidly and efficiently generate optimized monoclonal antibodies for therapeutic development, including neutralizing antibodies for enzyme inhibition applications.”

 

BioAtla’s proprietary Comprehensive Integrated Antibody Optimization (CIAO!TM) platform integrates important features of manufacturing and process development into protein design yielding superior antibody candidates. TPH 101 is designed to prevent devastating orthopedic periprosthetic joint infections and accompanying implant-associated osteomyelitis that can occur in total hip and knee replacement and other arthroplasty procedures.  These infections can be medically and financially devastating to patients, with treatment costs that can be 4-6 times the cost of the original operation alone. There are approximately 1.05 million total hip and knee replacement procedures performed annually in the United States today, with those procedures projected to cost nearly $120 billion by 2020. Treatment of periprosthetic joint infections in some patients who undergo these procedures is projected to cost our healthcare system $1.7 billion in that same year.  BioAtla is eligible to receive downstream proceeds in the form of milestone and royalty payments upon commercialization of TPH 101.

 

“BioAtla is a unique company and partner in this industry given its robust, proprietary platform for optimizing therapeutic antibodies,” said Mark Benedyk, president and chief executive officer of Telephus. “We are extremely pleased to move our lead program forward with BioAtla, who successfully advanced development of TPH 101 two months ahead of schedule.”

 

TPH 101

TPH 101 is a neutralizing monoclonal antibody that inhibits a key biofilm enzyme used by clinically significant strains of Staphylococcus aureus (including MRSA) to adhere to and colonize surfaces of implantable devices and tissue grafts, forming antibiotic-resistant biofilms in the process.

 

About BioAtla, LLC

BioAtla is a global biotechnology company with operations in San Diego, CA and Beijing. BioAtla develops novel monoclonal antibody and other protein therapeutic products with more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing. By utilizing its proprietary technologies of product design and development, from target discovery to manufacturing and preclinical studies, BioAtla develops differentiated, patentable therapeutic proteins for its partners and for its internal programs. BioAtla has over 70 patents pending that cover its platform technologies representing a full complement of therapeutic protein development capabilities. Learn more at www.bioatla.com.

 

About Telephus Medical LLC

Telephus is developing clinical products based on the groundbreaking work in bone health developed by Dr. Edward Schwarz, Director of the Center for Musculoskeletal Research and Distinguished Professor in Orthopaedics at the University of Rochester School of Medicine and Dentistry. Focused on the prevention of periprosthetic joint infections and osteomyelitis, Telephus’ lead program TPH 101 is designed to block staphylococcal adhesion and replication on the surfaces of implantable medical devices to prevent the formation of antibiotic-resistant periprosthetic biofilm infections and accompanying implant-associated osteomyelitis. Learn more at www.telephusmedical.com.

 

 

# # #

Contacts:
Richard Waldron

Chief Financial Officer

BioAtla

rwaldron@bioatla.com

858.356.8945

 

Mark Benedyk, Ph.D.

Telephus Medical

President and CEO

mbenedyk@telephusmedical.com

858.217.5647

Feb 19, 2014 | BioAtla Grants BioMotiv Exclusive Worldwide Rights to IL-22 Antibody for Inflammatory Bowel Diseases and Colorectal Cancer

SAN DIEGO, Calif. and CLEVELAND, Ohio – February 19, 2014 – BioAtla, a global biotechnology company focused on the development of conditionally active biologics (CABs), and BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery & Development, today announced that BioAtla licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases (IBD) and oncologic indications. In conjunction with the agreement, BioMotiv established Kodosil Bio which will develop all compounds resulting from the license.

 

“We believe BioMotiv will be an ideal partner to take the antibody forward into the clinic, building on our solid discovery foundation that demonstrates the value of this antibody in the potential treatment of a variety of disease indications where there is considerable unmet need in large market opportunities,” said Jay M. Short, Ph.D., president and chief executive officer of BioAtla. “This partnership is an ideal demonstration of the power of our proprietary platform to generate unique, therapeutically-active monoclonal antibodies for a variety of diseases, both for our partners – in this case BioMotiv – and for our proprietary product portfolio.”

 

BioAtla used its proprietary Comprehensive Integrated Antibody Optimization (CIAO!™) platform for the identification, humanization, and optimization of the monoclonal antibody. The CIAO! technology selects antibody candidates that integrate important features of manufacturing and process development into the protein design. This platform selects candidates with natural protein folding and glycosylation, high protein expression and faster downstream process development characteristics, enabling cost and time efficiencies throughout the development process.

 

Under the terms of the agreement, BioAtla will provide its proprietary discovery and preclinical development processes for the licensed compounds. Kodosil Bio will manage the development of the therapeutic antibody and will fund all discovery and development activities through clinical proof-of-concept. BioAtla will receive milestone payments and royalties on sales of all potential therapeutics developed through the collaboration. If the therapeutic antibody products developed through Kodosil Bio are sublicensed or divested, BioAtla will receive a substantial portion of proceeds resulting from the action.

 

“BioAtla is a unique company and partner in this industry given its robust, proprietary platform for identifying and developing promising therapeutic antibodies,” said Baiju R. Shah, chief executive officer of BoiMotiv.  “We are pleased to partner with them on this important opportunity, which targets an immunology pathway that is gaining increasing recognition for its role in multiple disease conditions.”

 

 

Antibody

The antibody is directed at a novel validated target in the TH22 cell/IL-22 pathway, which plays a key role in gastrointestinal autoimmune and inflammatory processes as evidenced by changes in expression in IBD and colorectal cancer (CRC) patients.

 

About BioAtla, LLC

BioAtla is a global biotechnology company with operations in San Diego, CA and Beijing. BioAtla develops novel monoclonal antibody and other protein therapeutic products with more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing. By utilizing its proprietary technologies of product design and development, from target discovery to manufacturing and preclinical studies, BioAtla develops differentiated, patentable therapeutic proteins for its partners and for its internal programs. BioAtla has over 70 patents pending that cover its platform technologies representing a full complement of therapeutic protein development capabilities. Learn more at www.bioatla.com.

 

About BioMotiv, LLC

BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $250 million national initiative for advancing medicine centered at University Hospitals of Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs. Products are advanced to clinical proof-of-concept and then partnered. BioMotiv is interested in early-stage therapeutics in all disease areas. Learn more at www.biomotiv.com.

 

 

 

# # #

Contacts:
Richard Waldron

Chief Financial Officer

BioAtla

rwaldron@bioatla.com

(858) 356-8945

 

Dawn Auvil

BioMotiv

dauvil@biomotiv.com

(216) 455-3217

Jul 2, 2013 | BioAtla Expands Senior Management Team to Bolster Partnering and Drug Development Activities

San Diego, California – 02 July 2013

BioAtla LLC, a protein therapeutics service provider with facilities in San Diego and Beijing, announced today the hiring of Dr. William J. Boyle as VP of Translational Medicine to join the senior research team that includes Dr. Cathy Chang, VP of R&D China and Dr. Gerhard Frey, VP of Scientific Programs and Collaborations.  Bill was most recently President of VivaMab, a drug development division of BioAtla involved in the discovery and development of therapeutic antibodies.  Prior to that he was President and Chief Science Officer at Anaptysbio, and former Director of Research at Amgen, Inc. where he led the discovery and early preclinical development of densoumab, a RANKL-targeted therapeutic antibody.

“Bill’s success and experience in the discovery and development of therapeutic proteins strengthens both our research and business teams.  Most importantly, it allows us to provide key insights to our partners involved in their own discovery programs, as well as to continue to assist with advancing BioAtla’s partnered, spin-out and divisional therapeutic programs into the clinic,” says Dr. Jay M. Short, Chairman and CEO of BioAtla.  BioAtla last week announced a partnership with ADC Therapeutics to develop a potent antibody drug conjugate for the treatment of hematologic cancers.  Data recently presented at the recent American Society of Clinical Oncology (ASCO http://chicago2013.asco.org/) from this collaboration underscores the utilization of the platform to produce best in class therapeutics.

Dr. Boyle will lead efforts to advance existing strategic partnerships, while also establishing new collaborative relationships in the area of protein therapeutics. “BioAtla’s technology platform is uniquely suited to address industry needs for the discovery and development of protein therapeutics and therapeutic antibodies,” says Boyle.  “In particular, the proprietary platforms are being used to create drug candidates with differentiated functionality and high therapeutic indices for clinical development.”

 

About BioAtla, LLC

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

For more information contact:

Dr. William Boyle

T: 858-558-0708 x3104

E: bboyle@bioatla.com

info@bioatla.com

Jun 24, 2013 | VivaMab and ADC Therapeutics Announce Antibody Licensing Deal for Novel ADC Candidate to Target Hematologic Cancers

San Diego, USA and Lausanne, Switzerland − 24 June 2013 − VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), today announced a licensing deal for a novel antibody against an undisclosed  hematological cancer target.

Under the terms of the deal, ADC Therapeutics has licensed a VivaMab antibody (VM101) produced using BioAtla’s Express Humanization™, Comprehensive Positional Evolution™, Combinatorial Protein Synthesis™ affinity and functional maturation technology platforms.  VM101 has been combined with a third-generation cytotoxic pyrrolobenzodiazepine (PBD)-based warhead and proprietary linker technology to form a novel ADC, which has already been shown to have powerful in vivo efficacy in established models for normally intractable hematological cancer indications.

ADC Therapeutics plans to initiate pre-IND development of this proprietary ADC immediately, in parallel with its other advanced ADC programs. VivaMab will provide development support and will receive a share of potential milestones and royalties on the drug. Financial terms were not disclosed and remain confidential.

Dr. William Boyle, President of VivaMab said: “The BioAtla platform has generated a superior internalizing antibody to the target of interest, allowing us to generate and develop an ADC drug candidate for hematologic cancers. The combination of a uniquely potent BioAtla antibody with a potent drug conjugate, or warhead, is likely to enhance therapeutic outcomes in its target indication.”

Dr. Peter B. Corr, Chairman of ADC Therapeutics and Managing General Partner of Auven Therapeutics said: “PBD-antibody conjugates are the most promising next-generation ADCs.    The target disease for this ADC is particularly sensitive to our PBD technology, with its functionally optimized conjugation and pharmaceutical properties that maintain activity in cancers resistant to other therapies including earlier generations of ADCs. We are very pleased to be working with VivaMab to bring this potentially exciting cancer therapeutic into clinical development.”

Results presented at the 2013 American Association for Cancer Research by BioAtla and Spirogen showed positive data describing the potent ADC activity which resulted from the combination of BioAtla’s functionally and CIAO!™ evolved antibody with Spirogen’s PBD-derived conjugate.  The pre-clinical studies, that evaluated in vivo performance against a hematologic cancer target, showed complete responses at low doses, and at low drug-antibody ratios, in each of the tumor types studied. The PBD dimers were not found to be cross-resistant with widely used chemotherapeutic agents.

Dr. Jay M. Short, CEO and Chairman of BioAtla sees future opportunities to pursue ADCs: “By creating an antibody that is optimized for expression, target binding and potency, BioAtla and ADCT are paving the way to make powerful next generation cancer drugs with the potential to save lives.”

About BioAtla LLC and VivaMab

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies, representing a full complement of therapeutic development capabilities, and VivaMab molecules.

BioAtla’s proprietary Comprehensive Integrated Antibody Optimization (CIAO!™) platform selected for natural protein folding and glycosylation, high protein expression and faster downstream process development enables cost-efficiencies by integrating the features important for manufacturing and process development into the design of the protein.  BioAtla’s latest proprietary platforms include manufacturing-efficient bi-specific antibodies, as well as Conditionally Active Biologics (CABs), antibodies that can be locally and reversibly activated at diseased tissues.

Formed in 2010, VivaMab is the therapeutic development division of BioAtla with a pre-clinical biologic portfolio that includes both first-in-class as well as best-in-class assets in oncology and immunology therapeutic areas.

To learn more, please visit: www.bioatla.com and www.vivamab.com

About ADC Therapeutics Sarl

ADC Therapeutics (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As its PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market. The company was formed in 2012 with a $50m commitment from private equity firm Auven Therapeutics (previously known as Celtic Therapeutics). ADCT has a strategic collaboration with Spirogen Ltd, also an Auven Therapeutics’ portfolio company, for the supply of warhead chemistries and R&D services. It operates a virtual business model based in Lausanne, Switzerland.

For further information please see: www.adctherapeutics.com

About Auven Therapeutics

Auven Therapeutics was founded by Stephen Evans-Freke and Dr. Peter B Corr in 2007 with an innovative investment strategy – while it is structured as a private equity fund, it also operates as a drug development company.  Auven Therapeutics has a portfolio of biologic and small molecule therapeutic candidates for a range of therapeutic indications including cancer, ophthalmic conditions, women’s health and orphan diseases. Auven manages its drug development activities from its bases in Lausanne, Switzerland, New York, USA and Hamilton, Bermuda.  Auven Therapeutics Management L.L.L.P., based in the U.S. Virgin Islands, serves as its Investment Advisor.

For further information please see: www.auventx.com

For enquiries:

 

VivaMab/BioAtla ADC Therapeutics/Auven Therapeutics
Dr. William BoyleT: 858-558-0708 x3104E: bboyle@bioatla.com

info@bioatla.com

College Hill Life Sciences (PR Agency)
T: +44 (0)20 7457 2020
E: adctherapeutics@collegehill.com

 

 

Apr 23, 2013 | BioAtla Combines EpiVax’s Immunogenicity Screening Into Their Express Humanization (TM) Platform

Providence and San Diego, 24 April 2013 – EpiVax Inc., an unique immunology company with a strong focus on immunogenicity mitigation and BioAtla, LLC, a San Diego headquartered antibody therapeutics developer, today announced a collaborative agreement to incorporate EpiVax’ proprietary immunogenicity screening technology into BioAtla’s antibody Express HumanizationTM platform.

 

EpiVax specializes in immunogenicity screening for protein therapeutics, immunogenicity mitigation and T cell-driven vaccine design, using a suite of proprietary in silico tools. These tools are based on the extensively validated EpiMatrix system. Their ISPRI-HT (for high-throughput) in silico analysis screens and triages large numbers of  antibodies for overall and relative immunogenic potential and identifies lower risk candidates to move forward. The EpiMatrix prediction has been shown in prospective studies (and retrospective studies) to correlate with clinical immunogenicity.[1] EpiMatrix is the only screening system system that takes into consideration Tregitopes (T regulatory epitopes), a unique EpiVax discovery that is associated with regulatory T cell induction (see website for Tregitope publications).

 

BioAtla’s proprietary Express HumanizationTM entails synthesizing a combinatorial library of non-human target monoclonal antibodies fused in frame to a validated collection of human frameworks, and screening for binding, function and expression. Unlike more traditional approaches such as CDR grafting, this powerful approach allows for the selection of the most favorable combinations of fully human frameworks in terms of maintaining, and improving, the binding activity of the parental antibody without the need to make back mutations. In addition, these antibodies are uniquely selected human therapeutics since they are simultaneously screened for expression (see CIAO!™) and other targeted characteristics with an elite set of expressed human frameworks selected in the manufacturing host.

 

The addition of EpiVax high-throughput EpiMatrix (ISPRI-HT) analysis to the clone selection from BioAtla’s Express HumanizationTM platform expands the functional selectivity of BioAtla’s unique expression-based humanization process by providing the third level clone selection criterion for developing human antibody therapeutics – immunogenicity. This rapid and powerful process is expected to increase the success rate of biotherapeutics relative to other technologies where downstream failures cost the industry millions of dollars and years of additional development time.

 

Dr. Annie De Groot, CEO/CSO of EpiVax said, “This collaboration brings two best-in-class technologies together to serve the needs of the biologics industry. Integration of EpiMatrix into the BioAtla platform will increase the likelihood of successful clinical development.”

 

About BioAtla

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

For more information, please visit www.bioatla.com.

 

About EpiVax

EpiVax, Inc. is a Providence, Rhode Island biotechnology company focused on the development of vaccines and immunotherapeutics. EpiVax is one of the world’s leading innovators in the field of ‘Immunogenicity Screening’. The Tregitope technology improves tolerance of protein drugs such as replacement enzymes, blood factors, and monoclonal antibodies. Through the application and utilization of these computational tools, EpiVax is helping to engineer safe, more effective therapeutic proteins and to rapidly design protective and efficacious new vaccines. Led by Dr. Anne S. De Groot, M.D., Immunoinformatics and vaccine design thought leader, EpiVax has enjoyed success in the fields of immunology and bioinformatics, and has developed proprietary immunoinformatics tools for the development and improvement of biotherapeutic drug candidates.

For more information, please visit www.epivax.com

 

Contact information for individuals willing to speak on the record regarding this collaboration:

 

David Wellis, Ph.D.

President, BioAtla, LLC

t: +1 858-558-0708 x3105

dwellis@bioatla.com

info@bioatla.com

 

Dr. Anne De Groot, MD

CEO/CSO EpiVax, Inc.

AnnieD@epivax.com

t: (401) 272-2123



[1] De Groot and Martin. Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clinical Immunology 2009. 131, 189-201.

 

Apr 8, 2013 | Spirogen and BioAtla Present Positive Data on Next-Generation Warheads in ADCs Against Cancer

Data Demonstrating Excellent Specificity Presented at AACR

London and San Diego, 8 April 2013 – Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

The study evaluated the efficacy of five ADCs against solid and hematological cancer targets. The hematological target antibody was engineered using BioAtla’s proprietary CIAO™ and BioAcceleration™ technologies and conjugated to Spirogen’s cytotoxic PBD dimers. Trastuzumab ADCs were tested against Her2-expressing human breast cancer in vivo.

For both tumour types data showed that the ADCs achieved durable complete regression and tumor free survival. The PBD dimers were not found to be cross-resistant with widely-used chemotherapeutic agents.

Professor John Hartley, lead author of the study and Director of Pre-clinical Development at Spirogen, said: “Significant activity at remarkably low doses and at low drug-antibody ratios was seen in all tumor types we studied. Antibody-PBD conjugates are the most promising next-generation oncology compounds for clinical development.”

Dr Jay M Short, Chairman and CEO of BioAtla, said: “By pairing our technologies with Spirogen’s warheads, we have achieved affinity and efficient internationalisation of these exciting novel ADCs.”

The AACR study, Abstract #2856, titled ‘Pyrrolobenzodiazepine (PBD) dimers – potent next generation warheads in antibody drug conjugates (ADCs) targeted at both solid and hematological tumors’, was authored by scientists from Spirogen, BioAtla, ADC Therapeutics, and UCL Cancer Institute, in London.

About Spirogen Limited
Spirogen Limited (“Spirogen”) was founded in 2001 as a spin-out from several institutions including University College, London. Since that time, it has developed a novel class of highly potent cytotoxic warheads based on its proprietary pyrrolobenzodiazepines (“PBD’s”), DNA minor groove binding agents, which bind and cross-link specific sites of DNA of the cancer cell. This blocks the cancer cells’ division without distorting its DNA helix, thus avoiding the common phenomenon of emergent drug resistance. In contrast, many cancer chemotherapeutics distort the structure of DNA resulting in the ability of the cancer cells to develop resistance to further therapy. Spirogen has been developing its PBD technology for more than ten years, including a standalone PBD agent already in an NCI-sponsored Phase II study in cisplatin resistant ovarian cancer. Its business model is to partner its technology with pharma and biotech for use in the development of novel drugs. It has a number of industry collaborations, including a collaboration with Genentech announced in 2011.
For further information, please visit Spirogen’s website, www.spirogen.com.

About BioAtla

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.
For more information, please visit www.bioatla.com.

About ADC Therapeutics
ADC Therapeutics sarl (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As its PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market. The company was formed in 2012. It has a strategic collaboration with Spirogen Ltd, a Celtic Therapeutics’ portfolio company, for the supply of warhead chemistries and R&D services. It operates a virtual business model based in Lausanne, Switzerland.
For further information please see: http://www.adctherapeutics.com/

About UCL Cancer Institute

The UCL Cancer Institute was established in 2007 and is the hub for cancer research at UCL. The Institute is located in the heart of London, and part of UCL [University College London]. UCL is consistently ranked within the top 20 global universities. The Cancer Institute is part of the Faculty of Medical Sciences, within the School of Life- and Medical Sciences. This School comprises the largest concentration of biomedical researchers in Europe. The Cancer Institute hosts the majority of cancer research at UCL, whilst other cancer activities across the UCL campus form part of a new Cancer Domain. The overall remit of the Institute is to develop a cancer presence and excellence, which rival other major national and international hubs for cancer research.

For media enquiries, please contact

Spirogen

Dr Chris Martin
CEO
m: +44 (0) 7788 720572

e: chris.martin@spirogen.com

BioAtla

David Wellis

t: +1 858-558-0708 x3105

e: dwellis@bioatla.com

info@bioatla.com

College Hill (for media enquiries)
Sue Charles, Stefanie Bacher, Gemma Howe, Donia Al-Saffar
t: +44 (0) 20 7866 7860
e: spirogen@collegehill.com

Oct 16, 2012 | BioAtla’s Spin-Out Company, VivaMab, in the News

BioAtla’s Spin-Out Company, VivaMab, is part of a recent CPB Review feature story on biobetters and improved biologics. For a PDF download of the full article, please click on the article title below.

Banking on a Big Biobetters Bonanza
Will China Use its Capabilities to Create Improved Biologics?
by Sabine Louiët
CPB Review Feature Story, Volume 60, 2012

 

CPB Review is published by GBI:
GBI (www.gbipharma.com) is China’s leader in pharmaceutical and biotechnology data intelligence and consulting services. GBI provides in-depth analysis and insights that enable subscribers to stay ahead of China’s pharmaceutical, biotechnology and healthcare industries. They offer Weekly Roundup- a free weekly updates on industry news, China Pharmaceutical & Biotechnology (CPB) Review – China’s premier monthly publication examining the latest industry trends, and SOURCE Information System- a data intelligence system adding value to every aspect of a pharmaceutical organization.

Mar 7, 2011 | Charles River and BioAtla announce partnership

–Companies collaborate to offer Integrated Biological Service for Preclinical Development

-

SAN DIEGO, Calif. Charles River and BioAtla have recently partnered to create an integrated biological service for antibodies and other protein therapeutics designed to accelerate drug development for customers from the earliest stages of discovery all the way through IND.

-

This new partnership combines world-class toxicology services with proprietary, state-of-the-art biological engineering capabilities and represents a significant milestone toward establishing one of the first fully integrated biological services partnership for antibodies and other protein therapeutics. In addition, the international reach of these preferred contract research organizations brings much needed cost-effective integrated services for pharmaceutical development.

-

About Charles River
Charles River, headquartered in Wilmington, MA, provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Its approximately 8,000 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. For more information, visit www.criver.com.

-

About BioAtla
Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

-

For more information, please visit www.bioatla.com or contact

-

Carolyn Anderson
Executive Vice President
BioAtla, LLC
10190 Telesis Court
San Diego, CA 92121
858-558-0708 ext. 0
info@bioatla.com

-

SOURCE BioAtla, LLC / Charles River Laboratories International, Inc.

Nov 8, 2010 | BioAtla Redefining the Business of Drug Discovery

– Company offers biotech firms new opportunities in wake of troubled global economy –

SAN DIEGO, Calif., November 8, 2010. BioAtla, LLC, a San Diego-based protein therapeutics services provider, wants drug discovery companies worldwide to know one thing about operating in today’s business climate – there is hope. While biotechnology companies tackle the traditional complexities of scientific discovery, they must also navigate amidst increasing business pressures fueled by rising costs and scarce funding. That’s where BioAtla thrives.

BioAtla helps biotechnology companies propel drug development forward by bringing a pioneering spirit that welcomes unique collaborations, backed by an expanding global infrastructure. Their business philosophy is simple: empower biotech firms with the scientific expertise they need, at a cost they can afford. How BioAtla achieves this is part art, and definitely part science.

“We offer leading-edge, comprehensive protein engineering services performed in China, which gives our clients cost-efficient access to technologies that would otherwise be unaffordable,” says Dr. Jay M. Short, Founder, Chairman and CEO of BioAtla. “Our corporate policy is to assign 100% ownership of products resulting from BioAtla services to our customers. And our technologies are proprietary, strengthening our clients’ intellectual property portfolios along the way. We help your organization create it, make it and own it.”

Dr. Short is no stranger to innovation. He’s the Founder and former CEO, President and CTO of Diversa Corporation (now British Petroleum and Verenium), where he achieved the largest biotech IPO at the time. He also served as President of Stratacyte, and VP of R&D and Operations for Stratagene Cloning Systems (now Agilent). With BioAtla, Dr. Short continues to push the envelope of innovative and proprietary technologies in the field of protein therapeutics. BioAtla’s CIAO! (Comprehensive Integrated Antibody Optimization™) technology platform for protein expression can select molecules in a manner that mirrors both the body’s environment and the host that will be used for final manufacturing of the drug – reducing downstream drug risk from early in the discovery process. And the company is pioneering “Only at BioAtla” services such as its recently launched Native Target Discovery platform.

While the company is garnering attention for its comprehensive scientific expertise, BioAtla is also making business collaborations that accelerate drug development a real art form. “Financial collaborations are rapidly replacing traditional drug discovery business models that simply are not longer financially sustainable. We’re not only willing, but highly interested in establishing a financial partnership to accelerate your company’s success,” says Dr. Short. One such collaboration is the partnership between BioAtla and Femta Pharmaceuticals; the two companies share a technology platform with BioAtla fulfilling the role of a services company while Femta seeks to develop therapeutic candidates.

Recently, BioAtla has taken their unique business approach to the web. Their newly branded website (http://www.bioatla.com) is organized to educate the user not only about the services the company is offering, but where the industry is headed. There is hope for a better drug discovery process. BioAtla calls it BioAcceleration™ and they are proving it works. The website was custom created for BioAtla by San Diego-based brand communication firm, Miriello Grafico. Some unique features of the site include a section about global collaboration, illustrating how the company works with their internationally located facilities to ensure quality and transparency, as well as an educational appendix section. In celebration of the website launch, BioAtla is offering visitors the opportunity to register-to-win a free 3G iPad with pre-loaded apps valued at $100. The contest runs through November 30, 2010.

-

 

About BioAtla, LLC

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

For more information, please visit www.bioatla.com or contact

Carolyn Anderson
Executive Vice President
BioAtla, LLC
10190 Telesis Court
San Diego, CA 92121
858-558-0708 ext. 0
info@bioatla.com

SOURCE BioAtla, LLC

Oct 7, 2010 | BioAtla introduces GigaMab™ Fully Human Antibody Platform

– New platform takes HuAb to the next level –

SAN DIEGO, Calif., October 7, 2010. BioAtla, LLC, announced a new Fully Human Antibody Platform with full-length antibodies and over 10^9 members expressed in mammalian cells. This proprietary, expanded and validated high diversity HuAb library is immediately available to BioAtla’s client partners.

The platform maintains the same screening timeframes of traditional methods while capitalizing on one of the most proven and safe glycosylating systems, reducing the potential for negative immunogenicity.

For more information, visit our GigaMab™ Fully Human Library informational page.

-

About BioAtla, LLC.

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

 

For more information, please visit www.bioatla.com or contact:

Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com

SOURCE BioAtla, LLC

Aug 27, 2010 | BioWorld Today cites innovative BioAtla/Femta collaboration

– Industry publication recognizes our unique collaboration with Femta –

An article appearing in the August 27, 2010 edition of BioWorld Today by Catherine Shaffer calls attention to the unique business partnership and shared technology platform between BioAtla (service provider) and Femta Pharmaceuticals (therapeutics discovery).

The article also refers to BioAtla as a contender for providing “best-in-class” antibodies via usage of rabbit physiology.

Read the entire article (Apexigen Exploits Unique Rabbit Physiology to Make Antibodies) by downloading the PDF.

Aug 2, 2010 | BioAtla inks 25th partnership, looks to continued growth

– Company that began in 2007 rapidly gains acceleration –

SAN DIEGO, Calif., August 18, 2010. BioAtla, LLC, announced the signing of its 25th partnership with institutions that include private and public companies and venture capital groups and academia from the across the US, Europe, Israel and South Korea.

The company continues to accelerate its expansion based on its unique combination of state-of-the-art technologies embedded into services that allow its clients to save costs and speed their development time to market.

A global outsourcing model has been embraced by many leading biotech companies and BioAtla is guiding these companies with best practices for overseas discovery and development.

-

About BioAtla, LLC.

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

 

For more information, please visit www.bioatla.com or contact:

Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com

SOURCE BioAtla, LLC

Feb 3, 2010 | San Diego Science Festival recipient of BioAtla goodwill

– Student festival gets boost from real world scientists –

SAN DIEGO, Calif., February 3, 2010. BioAtla, LLC, announced their continued support for the San Diego Science Festival, pledging both a monetary donation and a commitment to serve on the honorary board of directors.

Dr. Jay M. Short, CEO and Founder of BioAtla, will serve on the board along with Drs. Roger Tsien, Maryanne Fox, Craig Venter and other biotechnology veterans. BioAtla has been an active supporter of the festival that began in 2009. The festival includes hundreds of science-related school activities and public events, culminating in an annual Expo Day, noted as the largest single day celebration of science in the nation.

 

-

About BioAtla, LLC.

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

For more information, please visit www.bioatla.com or contact:

Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com

SOURCE BioAtla, LLC

Jan 19, 2010 | Halozyme announces research alliance with BioAtla

– Conditionally active biologics a centerpiece of the three year agreement –

In a recent statement – dateline SAN DIEGO, January 19, 2010 – Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.

During the initial three year term of the research collaboration, Halozyme will receive exclusive worldwide commercial rights from BioAtla to conditionally active biologics (CABs) that arise from the agreement.

For more details, download a PDF of the company’s entire press release here.

Dec 15, 2009 | BioAtla partner company to manufacture with Lonza

– Femta/Lonza targeting Rheumatoid Arthritis treatment –

BioAtla’s partner company, Femta Pharmaceuticals, recently announced an agreement with Lonza Group Ltd.

In a joint release by Femta Pharmaceuticals and Lonza – dateline San Diego, CA / Basel, Switzerland, 15 December 2009 – Femta Pharmaceuticals and Lonza Group Ltd announced the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101.

FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis. The agreement allows Femta access to Lonza’s GS Gene Expression System™.

For the entire release, download a PDF here.

Read more about Femta in the Wall Street Journal here.

Jun 11, 2009 | BioAtla announces novel system for optimizing proteins

– Say hello to Comprehensive Integrated Antibody Optimization: CIAO!

SAN DIEGO, Calif., June 11, 2009. BioAtla, LLC, announced a system for optimizing proteins, including antibodies for maximal expression and physiological function, dubbing the system CIAO!

The acronym stands for Comprehensive Integrated Antibody Optimization and represents the first demonstrated, fully integrated protein discovery, evolution and manufacturing system for protein therapeutics.

While protein engineering has traditionally been accomplished via systems that were simplest to work with, but not necessarily optimal for production, CIAO! eliminates the need to compromise. The system allows for selection of molecules in an environment that is both natural origin (i.e. mammalian cells) and optimized from the very beginning for their function and expression.

BioAtla has successfully demonstrated CIAO! from discovery through clinical scale manufacturing. This patent pending development and manufacturing technology is expected to speed protein therapeutic development and improve clinical efficacy.

Learn more at our CIAO! page.

-

About BioAtla, LLC.

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

 

For more information, please visit www.bioatla.com or contact:

Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com

SOURCE BioAtla, LLC

May 24, 2008 | Fully human antibody library introduced by BioAtla

– Innovative full-length IgG library expressed in Mammalian cells –

SAN DIEGO, Calif., May 24, 2008. BioAtla, LLC, announced the release of their proprietary fully human antibody library. HuAb-SD rapidly identifies antibodies for customer targets and reduces the time for generating promising therapeutic lead molecules. HuAb is completely compatible with BioAtla’s affinity maturation and expression platforms. Expressed in mammalian cells, the library allows customers to bypass many problems encountered with traditional techniques used in antibody engineering.

About BioAtla, LLC.

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

 

For more information, please visit www.bioatla.com or contact:

Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com

SOURCE BioAtla, LLC

May 10, 2008 | BioAtla founds Femta Pharmaceuticals

– Ongoing collaboration to fuel growth of both companies –

SAN DIEGO, Calif., May 10, 2008. BioAtla, LLC, has joined with Latterell Venture Partners to launch Femta Pharmaceuticals, an antibody development company. Femta’s initial drug pipeline was developed by BioAtla to deomonstrate the power of its technology platforms. Since BioAtla was established as a dedicated service provider, the formulation of Femta Pharmaceuticals allows BioAtla to maintain its service focus.

BioAtla also established an exclusive relationship to supply Femta with advanced protein engineering technologies to bioaccelerate™ Femta’s antibody development program. BioAtla’s proprietary ATLab™ technology platform was a key driver in the agreement. Contractual details remain confidential.

About BioAtla, LLC

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

 

About Femta Pharmaceuticals

Femta Pharmaceuticals is focused on the development of best in class therapeutic monoclonal antibodies for the treatment of various disease states. Our monoclonal antibodies have applications in the areas of inflammation, autoimmune disease andoncology. Femta develops high affinity, high specificity monoclonal antibodies withimproved effector functions as well as favorable safety and pharmacokinetic profiles. This is accomplished using proprietary protein engineering technology from BioAtla. The technology enables Femta to develop super high affinity humanized and/or human antibodies (sub pico molar to femto molar affinity) to potentially any target that meets our selection criteria. The high affinity of our antibodies will contribute to making our products more efficacious with better safety profiles, as well as potentially reducing drug dosage.

For more information, please visit www.bioatla.com or contact

Carolyn Anderson, Executive Vice President

BioAtla, LLC

858-558-0708 ext. 0

info@bioatla.com

SOURCE BioAtla, LLC

Jan 18, 2008 | BioAtla appoints Leslie Hickle as VP of Business Development

–  Biotech industry veteran to support company growth  –

SAN DIEGO, Calif., January 18, 2008. BioAtla, LLC, announces the addition of Leslie A. Hickle, Ph.D. as Vice President of Business Development for the West Coast. Dr. Hickle brings to BioAtla more than 20 years of industry leadership, and will concentrate on connecting drug discovery companies with the comprehensive services and “can do” BioAcceleration™ philosophy that enables clients of BioAtla to propel their drug discovery efforts forward.

“Leslie’s experience with start-up biotech companies and notable success developing new companies for growth make her perfectly suited to BioAtla’s mission,” said Jay M. Short, Ph.D., CEO and Founder of BioAtla. “At this time in our company’s development, Leslie’s depth of technical experience and product positioning add immense value to our executive team.”

About BioAtla, LLC

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

 

For more information, please visit www.bioatla.com or contact

Carolyn Anderson, Executive Vice President

BioAtla, LLC

858-558-0708 ext. 0

info@bioatla.com

SOURCE BioAtla, LLC

Jun 10, 2007 | BioAtla launches suite of antibody engineering tools

– Introduction of ATLab™ technologies is company’s latest breakthrough –

SAN DIEGO, Calif., June 10, 2007. BioAtla, LLC, today announced the release of a validated suite of tools to bioaccelerate™ antibody evolution and humanization of nonhuman antibodies. Coined ATLAb™, the platform provides rapid humanization of non-human antibodies, and has proven utility in improving antibody affinity, specificity, effector function, expression level, stability and solubility. The technology suite includes ATLAb™ Antibody Humanization, ATLAb™ Antibody Evolution and ATLAb™ Antibody Expression and Purification.

Jay M. Short, Ph.D., CEO and Founder of BioAtla stated that in addition to ATLab™, BioAtla’s Humanation™ technology allows for the evolution of mouse or other non-human antibodies info fully human antibodies. These fully human antibodies contain only human sequence and no mouse or non-human antibody sequence – while maintaining similar specificity as the starting antibody.

About BioAtla, LLC

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

 

For more information, please visit www.bioatla.com or contact:

Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com

SOURCE BioAtla, LLC

Apr 6, 2007 | BioAtla signs Capia IP as exclusive provider for intellectual property services

– IP firm key contributor to business strategy, client satisfaction of BioAcceleration™ company –

SAN DIEGO, Calif., April 6, 2007. Capia IP has been retained to provide business, licensing, legal options and intellectual property support for BioAtla’s BioAcceleration™ protein therapeutics services business.

Ms. Carolyn Anderson, founder of Capia IP, stated “more and more companies understand that intellectual property strategy is a key component of business strategy. IP is literally the company’s jewels and the early discussion and implementation of IP strategy can add tremendous assets to a company’s portfolio as well as reduce long term costs by identifying and reducing unnecessary and distracting issues.”

Capia IP expertise ranges from biotechnology, pharmaceutical, agricultural, chemical and industrial technologies.

The two companies expect that their collaboration will allow rapid analysis and identification of potential issues for both BioAtla’s internal programs and partnering projects.

About BioAtla, LLC

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

 

About Capia IP

Capia IP collaborates with enterprises and individuals in life sciences to strategically manage and maximize the value of their intellectual property needs in view of their business. As a dedicated business partner of BioAtla, LLC, Capia IP offers BioAtla client partners comprehensive IP services to create, own and protect their results.

For more information, please visit www.bioatla.com or contact:

Carolyn Anderson, Executive Vice President

BioAtla, LLC

858-558-0708 ext. 0

info@bioatla.com

SOURCE BioAtla, LLC / Capia IP

Mar 29, 2007 | BioAtla establishes new contract business platform for protein engineering

- Company launched as sister company to BioDuro for protein therapeutics -

SAN DIEGO, Calif., March 29, 2007. BioAtla announced that its operations in San Diego and Beijing will be the first to provide global contract services solely focused on protein therapeutics.

Founded by Dr. Jay M. Short, Dr. Masood Tayebi and Carolyn Anderson, the company is following the successful strategy implemented by their earlier sister company, BioDuro, who found that it could increase the odds of success for early stage biotech companies by allowing them to outsource several key functions in combinatorial chemistry and clinical trials.

Protein therapeutics, specifically antibodies, is the fastest growing sector of the pharmaceutical industry. BioAtla’s 4th generation protein optimization technologies combined with a multinational professional staff will enable biotech startups and major pharmaceutical companies to cost effectively accelerate their protein-based drug programs.

About BioAtla, LLC

Founded in 2007, BioAtla is a global, biotechnology company based in San Diego, CA with operations in San Diego, and Beijing using a global infrastructure to develop potent and highly differentiated therapeutics with a strong IP position. By pairing antibody drug conjugates (ADCs) with our patented conditionally active biologics (CABs), we are changing the future of medicine. BioAtla has over 70 patents pending covering its platform technologies representing a full complement of therapeutic development capabilities.

For more information, please visit www.bioatla.com or contact:

Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708
info@bioatla.com

SOURCE BioAtla, LLC

Mar 3, 2007 | Industrial Biotechnology profiles BioAtla founder, Dr. Jay M. Short

– Dr. Short the subject of sustainable bioscience article –

Leading industry publication, Industrial Biotechnology, recently profiled BioAtla founder, Dr. Jay M. Short. The article – titled “Diversity in vision and expertise: Jay Short promotes sustainable bioscience” – discusses some of Jay’s recent accomplishments and offers his perspective on meaningful success in the bioscience industry. Read the article at liebertonline.com